Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fampridine-SR in Multiple Sclerosis
NCT00127530Phase 3Completed
- Sponsor
- Acorda Therapeutics
- Start
- May 2005
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Fampridine-SR with Placebo (2 arms). Primary endpoint: Proportion of Timed Walk Responders at 14 weeks. Started May 2005; status: completed.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00127530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00127530.